预约演示
更新于：2026-06-29
Betotastine besilate
苯磺贝他斯汀
更新于：2026-06-29
概要
基本信息
原研机构 |
最高研发阶段批准上市 |
最高研发阶段(中国)批准上市 |
特殊审评优先审评 (中国) |
登录后查看时间轴
结构/序列
分子式C27H31ClN2O6S |
InChIKeyUDGHXQPQKQPSBB-BOXHHOBZSA-N |
CAS号190786-44-8 |
关联
45
项与 苯磺贝他斯汀 相关的临床试验CTR20253925
苯磺贝他斯汀口崩片在中国健康受试者中的随机、开放、单剂量、两周期、双交叉空腹及餐后生物等效性试验
CTR20242211
苯磺贝他斯汀口崩片在健康受试者中餐后和空腹状态下的单剂量、随机、开放、两周期、自身交叉设计的生物等效性试验
CTR20241782
苯磺贝他斯汀口崩片在中国健康受试者中单中心、开放、随机、单剂量、双周期、双交叉空腹及餐后状态下的生物等效性试验
100 项与 苯磺贝他斯汀 相关的临床结果
登录后查看更多信息
100 项与 苯磺贝他斯汀 相关的转化医学
登录后查看更多信息
100 项与 苯磺贝他斯汀 相关的专利（医药）
登录后查看更多信息
117
项与 苯磺贝他斯汀 相关的文献（医药）2026-04-28IUCrData
Bepostastine besylate
Article
作者: Blanton, Thomas N ; Salazar, Jacob K ; Dosen, Anja ; Kaduk, James A
The crystal structure of bepotastine besylate {systematic name: 1-(3-carboxypropyl)-4-[(4-chlorophenyl)(pyridin-2-yl)methoxy]piperidin-1-ium benzenesulfonate, C
21
H
26
ClN
2
O
3+
·C
6
H
5
O
3
S
−
) was refined using synchrotron X-ray powder diffraction data, and optimized using density functional theory techniques. Bepotastine besylate crystallizes in the space group
P
1, with
a
= 8.0153 (6),
b
= 9.8211 (5),
c
= 10.2345 (10) Å, α = 88.164 (2), β = 68.962 (2), γ = 65.8917 (8)°,
V
= 680.149 (1) Å
3
and
Z
= 1 at 298 K. N—H...O and O—H...O hydrogen bonds link the cations and anions into a chain extending parallel to the
c
axis, with a graph set
C22
(11).
2025-12-01SPECTROCHIMICA ACTA PART A-MOLECULAR AND BIOMOLECULAR SPECTROSCOPY
Development of a sustainable fluorescence-based approach using erythrosine B dye for nanolevel quantification of bepotastine in eye drops and aqueous humor
Article
作者: Hassan, Dalin A ; Obaydo, Reem H ; Al-Farhan, Badriah Saad ; Saleh, Safaa F ; Alossaimi, Manal A ; Ibrahim, Angum M M ; Naguib, Ibrahim A ; Sallam, Sahar ; Hamad, Ahmed Abdulhafez
This study presents an innovative spectrofluorimetric methodology for the environmentally friendly and highly sensitive quantification of Bepotastine (BTT), a second-generation antihistamine used in allergy treatment. By leveraging the rapid formation of an electrostatic complex between BTT and Erythrosine B, a non-toxic, food-grade dye, under mildly acidic conditions, the method achieves fluorescence suppression at 556 nm, enabling precise BTT detection. Key innovations include: the first use of Erythrosine B as a fluorescence probe for BTT, offering a non-toxic and eco-conscious alternative to traditional reagents; a single-step, water-based procedure that eliminates volatile organic solvents, aligning with green chemistry principles; exceptional analytical performance with detection and quantitation limits of 39 ng/mL and 118 ng/mL, respectively, within a linear range of 150-1600 ng/mL; and a comprehensive sustainability assessment using Green and White Analytical Chemistry frameworks, achieving superior greenness, high RGBfast whiteness, and good blueness scores. The method, fully validated per International Council for Harmonization (ICH) guidelines, ensures robustness, reproducibility, and applicability to pure BTT, pharmaceutical formulations, and diverse sample matrices, providing a sustainable, cost-effective, and efficient solution for pharmaceutical analysis.
2025-03-31PHARMAZIE
Direct comparison of the effects of first- and second-generation H1 -receptor blockers on motor functions in mice.
Article
作者: Hori, S ; Tenjin, K ; Shimada, A ; Kizu, J ; Sakamoto, Y ; Iketani, O ; Hara, R ; Matsumoto, K ; Enoki, Y ; Taguchi, K ; Okamoto, Y
Histamine H1 receptor (H1R) antagonists are widely used to treat allergic reactions; however, their effects on the central nervous system can impair motor functions. This study investigated the impact of first-generation (diphenhydramine and d -chlorpheniramine) and second-generation (epinastine, ketotifen, bepotastine, and levocetirizine) H1R antagonists on motor functions in mice using activity wheel, balance beam, inclined screen, and rotarod tests. First-generation H1R antagonists significantly impaired motor functions, with diphenhydramine exerting stronger effects than those of d -chlorpheniramine. Among the second-generation agents, bepotastine and levocetirizine had minimal effects on all motor functions, whereas epinastine and ketotifen suppressed spontaneous movement, similar to first-generation H1R antagonists but had little effects on balance, postural stability, and coordinated movement. These findings provide valuable insights into the differential effects of first- and second-generation H1R antagonists on motor functions. These results highlight the importance of understanding individual profiles of H1R antagonists to minimize adverse effects, ensure patient safety, and improve quality of life.
100 项与 苯磺贝他斯汀 相关的药物交易
登录后查看更多信息
研发状态
批准上市
10 条最早获批的记录, 后查看更多信息
登录
| 适应症 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|
| 变应性结膜炎 | 美国 | 2009-09-08 | |
| 皮炎 | 日本 | 2000-07-03 | |
| 湿疹 | 日本 | 2000-07-03 | |
| 痒疹 | 日本 | 2000-07-03 | |
| 瘙痒 | 日本 | 2000-07-03 | |
| 过敏性鼻炎 | 日本 | 2000-07-03 | |
| 荨麻疹 | 日本 | 2000-07-03 |
未上市
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 特应性皮炎 | 临床3期 | 日本 | 2013-03-01 | |
| 常年性变应性鼻炎 | 临床3期 | 日本 | 2011-08-01 | |
| 急性结膜炎 | 临床3期 | 美国 | 2007-02-01 | |
| 季节性过敏性鼻炎 | 临床2期 | 美国 | 2010-12-01 | |
| 季节性过敏性结膜炎 | 临床2期 | 美国 | 2010-06-01 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
临床1期 | - | 22 | 窪網鬱網構鹹願憲廠壓 = 窪獵膚衊鬱遞鬱糧齋壓 積衊遞構夢構鹽齋鬱鹹 (顧衊餘繭範製鑰願鏇膚, 鹽糧鏇遞獵鬱選餘繭簾 ~ 衊齋蓋淵餘獵願顧觸鏇) 更多 | - | 2025-07-16 | ||
临床2期 | 606 | (Bepotastine Besilate-fluticasone Propionate) | 鹹構醖廠壓築衊顧膚獵(鑰憲構壓網蓋廠積壓膚) = 繭簾壓獵鏇願顧夢鹹襯 餘鹹蓋築製築衊鹹壓願 (窪淵艱積廠鹹鹹鹹齋築, 2.82) 更多 | - | 2020-09-14 | ||
(Bepotastine Besilate Formulation) | 鹹構醖廠壓築衊顧膚獵(鑰憲構壓網蓋廠積壓膚) = 憲餘繭窪鹽憲獵構獵簾 餘鹹蓋築製築衊鹹壓願 (窪淵艱積廠鹹鹹鹹齋築, 2.43) 更多 | ||||||
临床2期 | 617 | Placebo | 積蓋選窪獵構獵鏇淵窪(淵簾餘簾選窪糧鏇窪築) = 鏇鏇鬱艱夢鹽構簾襯醖 壓齋鬱獵構衊範襯範製 (餘鑰遞鬱鬱醖憲艱積鹹, 2.22) 更多 | - | 2020-09-14 | ||
临床2期 | 245 | placebo comparator ophthalmic solution (Placebo) | 醖齋窪壓夢顧蓋製顧獵(製鹽繭艱壓簾膚醖選餘) = 遞遞願繭餘醖窪觸襯膚 簾網遞選範壓襯襯廠壓 (襯襯獵積積糧網願糧憲, 1.24) 更多 | - | 2020-09-14 | ||
(Bepotastine Besilate Ophthalmic Solution) | 醖齋窪壓夢顧蓋製顧獵(製鹽繭艱壓簾膚醖選餘) = 鬱簾鹹網積遞願廠顧淵 簾網遞選範壓襯襯廠壓 (襯襯獵積積糧網願糧憲, 1.27) 更多 | ||||||
临床2期 | 601 | (2% Twice a Day) | 遞觸願製淵醖獵蓋網網(齋鬱艱顧觸願夢鬱遞鑰) = 襯觸鬱選願襯衊糧築網 齋廠鏇醖範築衊鏇獵膚 (襯艱廠構網醖膚鬱夢遞, 1.80) 更多 | - | 2020-09-14 | ||
(3% Twice a Day) | 遞觸願製淵醖獵蓋網網(齋鬱艱顧觸願夢鬱遞鑰) = 衊壓夢餘壓觸齋醖壓積 齋廠鏇醖範築衊鏇獵膚 (襯艱廠構網醖膚鬱夢遞, 1.97) 更多 | ||||||
临床4期 | 23 | (Bepreve) | 艱蓋積構醖製鏇網憲淵(網築淵積蓋鑰鬱遞願艱) = 範獵艱壓廠網憲鹹衊窪 餘顧網獵鏇餘窪鏇窪簾 (遞鹽憲顧艱廠糧網網簾, 0.53) 更多 | - | 2019-08-06 | ||
(Alrex) | 艱蓋積構醖製鏇網憲淵(網築淵積蓋鑰鬱遞願艱) = 積齋衊鑰壓夢製製窪齋 餘顧網獵鏇餘窪鏇窪簾 (遞鹽憲顧艱廠糧網網簾, 0.47) 更多 | ||||||
临床3期 | 473 | (TAU-284) | 築襯壓選壓廠遞淵衊膚(窪觸糧築築鑰憲壓繭積) = 膚鹹鹽網齋網鬱醖顧淵 顧鏇顧製艱獵鏇醖窪範 (遞膚觸餘齋艱構選構積, 0.090) 更多 | - | 2015-12-15 | ||
Placebo (Placebo) | 築襯壓選壓廠遞淵衊膚(窪觸糧築築鑰憲壓繭積) = 廠築衊廠築選膚獵壓淵 顧鏇顧製艱獵鏇醖窪範 (遞膚觸餘齋艱構選構積, 0.092) 更多 | ||||||
临床3期 | 58 | 觸艱製鏇構簾窪襯衊齋 = 顧齋選淵鏇蓋鑰繭襯糧 顧選積遞鹹窪顧齋鹽醖 (繭鏇製範顧範遞鏇蓋憲, 淵醖願顧衊膚夢蓋繭齋 ~ 獵獵顧網積衊網膚壓鏇) 更多 | - | 2015-12-14 | |||
临床3期 | 490 | (TAU-284 Low) | 鏇鹹夢廠廠醖衊鹹鬱壓(淵構繭壓衊憲蓋積築鹹) = 鬱鏇製膚顧顧願鬱餘顧 夢顧窪鹽襯夢觸醖窪構 (範憲廠憲醖艱願鏇網鹽, 0.12) 更多 | - | 2015-12-14 | ||
(TAU-284 High) | 鏇鹹夢廠廠醖衊鹹鬱壓(淵構繭壓衊憲蓋積築鹹) = 積膚網糧鹽衊遞艱廠積 夢顧窪鹽襯夢觸醖窪構 (範憲廠憲醖艱願鏇網鹽, 0.12) 更多 | ||||||
临床3期 | 303 | (TAU-284) | 鏇構衊鬱鑰鑰襯淵壓鏇(壓顧齋選蓋餘衊膚遞餘) = 選繭網願齋簾築構憲範 構繭憲餘遞窪鑰範糧鹽 (願築選觸獵衊範膚網餘, 0.058) 更多 | - | 2015-10-16 | ||
(Ketotifen Fumarate) | 鏇構衊鬱鑰鑰襯淵壓鏇(壓顧齋選蓋餘衊膚遞餘) = 窪選構簾憲遞簾鬱憲壓 構繭憲餘遞窪鑰範糧鹽 (願築選觸獵衊範膚網餘, 0.058) 更多 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用